Zelboraf

Non-Small Cell Lung Carcinoma, Erdheim-Chester Disease, Metastatic Melanoma + 1 more
Treatment
2 FDA approvals
20 Active Studies for Zelboraf

What is Zelboraf

VemurafenibThe Generic name of this drug
Treatment SummaryVemurafenib is a medication that works by blocking the activity of specific mutated proteins involved in cancer growth. It was developed by Roche and Plexxikon, and approved by the FDA in 2011. It is used to treat certain types of melanoma, and Roche and Genentech have launched a development program for other potential uses.
Zelborafis the brand name
image of different drug pills on a surface
Zelboraf Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zelboraf
Vemurafenib
2011
1

Approved as Treatment by the FDA

Vemurafenib, otherwise called Zelboraf, is approved by the FDA for 2 uses including Unresectable Melanoma and Metastatic Melanoma .
Unresectable Melanoma
Metastatic Melanoma

Effectiveness

How Zelboraf Affects PatientsThe drug vemurafenib works by blocking the BRAF protein, which has been linked to cell growth, proliferation, and metastasis. It has been shown to reduce all markers of BRAF activation, as well as reduce the amount of cytoplasmic phosphorylated ERK and cellular proliferation driven by Ki-67. Studies have also shown that vemurafenib almost completely blocks the MAPK pathway.
How Zelboraf works in the bodyVemurafenib is a drug taken orally that works to prevent cancer growth. It specifically targets mutated BRAF-serine-threonine kinase, blocking downstream processes so that the tumor cannot grow and eventually dies. It is most effective against BRAF V600E mutation and has no effect on melanoma cells with normal BRAF mutations.

When to interrupt dosage

The proposed measure of Zelboraf is contingent upon the identified condition, including Non-Small Cell Lung Carcinoma, Erdheim-Chester Disease and Unresectable Melanoma. The measure of dosage fluctuates as per the technique of delivery (e.g. Tablet or Tablet - Oral) featured in the following table.
Condition
Dosage
Administration
Non-Small Cell Lung Carcinoma
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Metastatic Melanoma
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Unresectable Melanoma
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Erdheim-Chester Disease
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Zelboraf has a single contraindication, so it shouldn't be employed while encountering any of the conditions specified in the below table.Zelboraf Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Zelboraf.
Common Zelboraf Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Vemurafenib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Vemurafenib.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Vemurafenib.
Amodiaquine
Major
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amodiaquine.
Artefenomel
Major
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artefenomel.
Zelboraf Toxicity & Overdose RiskReports of toxicity suggest that taking too much of this medication could lead to an increased risk of skin cancer or faster growth of existing tumors.
image of a doctor in a lab doing drug, clinical research

Zelboraf Novel Uses: Which Conditions Have a Clinical Trial Featuring Zelboraf?

127 active trials are examining the effectiveness of Zelboraf in alleviating Metastatic Melanoma, Unresectable Melanoma and Erdheim-Chester Disease.
Condition
Clinical Trials
Trial Phases
Non-Small Cell Lung Carcinoma
0 Actively Recruiting
Unresectable Melanoma
39 Actively Recruiting
Phase 2, Phase 1, Phase 3
Erdheim-Chester Disease
0 Actively Recruiting
Metastatic Melanoma
94 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Zelboraf Reviews: What are patients saying about Zelboraf?

5Patient Review
3/3/2012
Zelboraf for Malignant Melanoma with BRAF V600E Mutation
4Patient Review
3/6/2019
Zelboraf for Malignant Melanoma with BRAF V600E Mutation
Zelboraf has been working for me since four weeks after I started taking it, which is much sooner than recommended. I only take two every twelve hours, and have had to stop a few times due to itch rashes. Despite this, Zelboraf has helped shrink one of my tumors from 13 cm to 8 cm in such a short time.
2Patient Review
12/15/2013
Zelboraf for Malignant Melanoma with BRAF V600E Mutation
Unfortunately, my family member experienced terrible burns after taking this drug for just two months. They were bedridden for an additional two months and are still recovering today.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zelboraf

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What protein is targeted by Zelboraf?

"The drug Vemurafenib specifically targets the protein BRAF that has the V600E mutation. By interfering with the abnormal BRAF signals, the growth of the cells is slowed or even stopped."

Answered by AI

What is vemurafenib prescribed for?

"Vemurafenib is used to treat certain types of melanoma (a type of skin cancer) that cannot be treated with surgery, or that has spread to other parts of the body. It is also used to treat a certain type of Erdheim-Chester disease (ECD; a disease that causes an overproduction of a type of white blood cells)."

Answered by AI

How long do you take Zelboraf?

"You should start taking ZELBORAF on the same day you start taking COTELLIC. Take ZELBORAF two times a day with or without food

You should take Cotellic and Zelboraf exactly as your healthcare provider tells you. This includes not changing your dose or stopping taking the medication unless your healthcare provider tells you to. You should take Cotellic once a day for 21 days, followed by 7 days off of the medication. This completes a 28-day treatment cycle. You should start taking Zelboraf on the same day that you start taking Cotellic. You should take Zelboraf two times a day with or without food."

Answered by AI

Is vemurafenib chemotherapy?

"A targeted therapy is a drug that targets the cancer’s genetic changes (mutation).

Zelboraf is a targeted therapy drug that is used to treat cancer by targeting the cancer's genetic changes. The generic name for Zelboraf is vemurafenib."

Answered by AI

Clinical Trials for Zelboraf

Have you considered Zelboraf clinical trials? We made a collection of clinical trials featuring Zelboraf, we think they might fit your search criteria.
Have you considered Zelboraf clinical trials? We made a collection of clinical trials featuring Zelboraf, we think they might fit your search criteria.
Have you considered Zelboraf clinical trials? We made a collection of clinical trials featuring Zelboraf, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top